A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Ependymoma
Ewing Sarcoma
High-grade Glioma
Leukemia and Lymphoma
Medulloblastoma
Miscellaneous Brain Tumors
Miscellaneous Solid Tumors
Neuroblastoma
Relapsed, Refractory Malignant Neoplasms
Rhabdomyosarcoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: NKTR-214

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]